Views:489 Author:Site Editor Publish Time: 2021-07-26 Origin:Site
The Center for Disease Control and Prevention (CDC) of Wuhan City, China, conducted a study on the specimens of the previous patients with flu-like illness，and published the study report entitled "SARS-CoV-2 Detection in Patients with Influenza-Like Illness" in Nature Microbiology.
A total of 640 throat swab samples were collected from patients with influenza-like illnesses (with the symptoms including fever, cough or sore throat) attending 2 sentinel hospitals in Wuhan from 6 October 2019 to 21 January 2020.
The nucleic acids were initially extracted from the samples (throat swabs) using Tianlong PANA9600E automated nucleic acid extraction system, then were tested for the presence of SARS-CoV-2 and the influenza virus by real-time PCR assays. The targets of the assays were both the ORF1ab and N gene of SARS-CoV-2, and the detection limit was 1,000 copies/ml.
Results and Conclusions
9 of the 640 throat swabs were positive for SARS-CoV-2 RNA, and 142 were influenza virus-positive. The 9 patients with COVID-19 came from 6 districts of the Wuhan metropolitan and surrounding areas, and the earliest sample collection date among them was 4 January 2020, suggesting that there was community transmission in Wuhan in early January 2020.
Tianlong Intelligent Manufacturing for Wuhan Unlocking
As an innovative pioneer in the molecular diagnostic industry, Tianlong provided nucleic acid detection products to Wuhan immediately after the outbreak, and helped the prevention and control of the epidemic at an early stage. During the fight against COVID-19, Tianlong products were widely used to equip Hubei Provincial CDC and Wuhan CDC, Tongji Hospital, Union Hospital, Hubei General Hospital among numerous local medical institutions, reported by CCTV News in various broadcasts. Among them, Wuhan CDC was equipped with multiple Tianlong nucleic acid extractors and automated nucleic acid workstations with corresponding supporting reagents, which rapidly improved the daily nucleic acid testing capacity and thus assisted the clinical diagnosis and epidemic prevention and control.
In the future, Tianlong will persist in “Intelligent Manufacturing from China”, and continue to develop first-class molecular diagnostic products for human well-being.